The Combined Usage of Clinical Physical Finding in Management of COVID 19 Patients

Physiological indicators such as blood pressure, heart rate, respiratory rate, and consciousness status of COVID-19 patients are used to apply the START (simple triage and rapid treatment, START), Modified Early Warning Score (MEWS), and quick Sequential Organ Failure Assessment (qSOFA) as tools for assessing clinical symptom tracking, deterioration, and subsequent improvement in COVID-19 patients. In response to the need for scarce manpower when a large number of emergency patients appear, a simple and easy-to-operate assessment method is adopted for mild patients, and artificial intelligence technology can be further used to assist in the assessment for early response and medication.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Pandemic COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

St. Martin De Porres Hospital

Tainan, 60069, Taiwan

About this study

Due to the development of the pandemic , the virus has constantly mutated, leading to a vast majority of mild cases. This has significantly increased the burden on medical personnel. The investigators are trying to find a way to track whether their clinical symptoms have worsened. At the same time, the investigators want to know the changes in patient symptoms in real-time through online monitoring This is a single-center retrospective study of a group of COVID-19 patients. Review their medical records, mainly based on hospital field records and existing physiological indicators of patients such as blood pressure, heart rate, respiratory rate, and consciousness status. The partients visited the hospital between March 2020 and September 2022. All patients were given physiological value indicators MEWS, qSOFA, and START for scoring and assess the clinical symptom deterioration of COVID-19 patients.

In this study, The investigators collect the physiological values of each patient and the data on the nursing records during hospitalization to judge whether the symptoms have worsened

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

a group of hospitalized COVID 19 patients were treated in the hospital between March 2020 and Sep.2022

Exclusion criteria

Exclude patients who lack information in their medical records and incomplete clinical data.

Treatment and study plan

COVID 19 pandemic

Other

Physiological indicators such as blood pressure, heart rate, respiratory rate, and consciousness status of COVID-19 patients are used to apply the START, MEWS, and qSOFA in COVID-19 patients.(COVID 19 病患).

Primary outcomes

COVID 19 pandemic

Time frame: March 2020 and September 2022

Assessing clinical symptom tracking, deterioration, and subsequent improvement in COVID-19 patients.

Sponsors and collaborators

Lead sponsor

St. Martin De Porress Hospital

Other

Registry information

Official study title

The Combined Usage of Clinical Physical Finding With Simple Triage and Rapid Treatment (START), Modified Early Warning Score(MEWS)and Quick Sequential Organ Failure Assessment(qSOFA) in Management of COVID 19 Patients

Important dates

Study start: 2020
Primary completion: 2022
Study completion: 2024
First posted: Jul 30, 2024
Registry last updated: Aug 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed